Coronavirus disease 2019 and pediatric asthma: friend or foe?
Curr Opin Allergy Clin Immunol
; 22(2): 95-100, 2022 04 01.
Article
in English
| MEDLINE | ID: covidwho-1864992
ABSTRACT
PURPOSE OF REVIEW The interplay of asthma and coronavirus disease 2019 (COVID-19) in children is yet unknown. The purpose of this review is to determine the interplay of asthma and asthma therapeutics and COVID-19. RECENT FINDINGS:
There is no evidence to date that asthma is a risk factor for more severe COVID-19 outcomes, especially in children. There is actually some basis to suggest that children with atopic asthma may be at reduced risk of asthma exacerbations during COVID-19. The impact of asthma therapeutics on COVID-19 outcomes is unclear, but guidance is relatively uniform in recommending that those with asthma remain on current asthma medications. A focus on social determinants of health may be increasingly important during the pandemic and beyond.SUMMARY:
Asthma in children appears to be more friend, than foe, during COVID-19.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Asthma
/
COVID-19
Type of study:
Observational study
/
Prognostic study
Limits:
Child
/
Humans
Language:
English
Journal:
Curr Opin Allergy Clin Immunol
Journal subject:
Allergy and Immunology
Year:
2022
Document Type:
Article
Affiliation country:
ACI.0000000000000809
Similar
MEDLINE
...
LILACS
LIS